Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 34 | 2020 | 151 | 9.940 |
Why?
|
| Bronchodilator Agents | 13 | 2020 | 56 | 3.840 |
Why?
|
| Glycopyrrolate | 3 | 2019 | 3 | 2.000 |
Why?
|
| Muscarinic Antagonists | 3 | 2019 | 14 | 1.860 |
Why?
|
| Lung | 7 | 2019 | 255 | 1.740 |
Why?
|
| Patient Readmission | 3 | 2017 | 125 | 1.550 |
Why?
|
| Smoking | 13 | 2016 | 500 | 1.530 |
Why?
|
| Asbestos | 5 | 2015 | 8 | 1.490 |
Why?
|
| Forced Expiratory Volume | 11 | 2019 | 97 | 1.170 |
Why?
|
| Asthma | 6 | 2018 | 297 | 1.120 |
Why?
|
| Mesothelioma | 3 | 2015 | 39 | 1.080 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2018 | 11 | 1.070 |
Why?
|
| Disease Progression | 4 | 2017 | 594 | 1.040 |
Why?
|
| Administration, Inhalation | 10 | 2019 | 57 | 0.990 |
Why?
|
| Ethanolamines | 2 | 2015 | 9 | 0.930 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 128 | 0.790 |
Why?
|
| Spirometry | 4 | 2019 | 30 | 0.740 |
Why?
|
| Humans | 44 | 2020 | 32025 | 0.730 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2018 | 33 | 0.730 |
Why?
|
| Glucocorticoids | 2 | 2012 | 148 | 0.690 |
Why?
|
| Respiratory System Agents | 1 | 2019 | 1 | 0.680 |
Why?
|
| Quinolones | 1 | 2019 | 7 | 0.680 |
Why?
|
| Middle Aged | 26 | 2020 | 11868 | 0.680 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2015 | 9 | 0.670 |
Why?
|
| Indans | 1 | 2019 | 31 | 0.670 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 71 | 0.640 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 900 | 0.620 |
Why?
|
| Aged | 22 | 2020 | 10340 | 0.610 |
Why?
|
| Vital Capacity | 5 | 2019 | 44 | 0.610 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 409 | 0.600 |
Why?
|
| Medicare | 2 | 2017 | 207 | 0.590 |
Why?
|
| Male | 29 | 2020 | 19196 | 0.590 |
Why?
|
| Female | 28 | 2020 | 19954 | 0.580 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 1067 | 0.580 |
Why?
|
| Germ-Line Mutation | 2 | 2015 | 18 | 0.570 |
Why?
|
| Drug Combinations | 4 | 2019 | 95 | 0.540 |
Why?
|
| Treatment Outcome | 8 | 2019 | 3317 | 0.520 |
Why?
|
| Coronary Disease | 2 | 2016 | 213 | 0.520 |
Why?
|
| Benzyl Alcohols | 1 | 2015 | 1 | 0.510 |
Why?
|
| Chlorobenzenes | 1 | 2015 | 2 | 0.510 |
Why?
|
| Quinuclidines | 1 | 2015 | 3 | 0.510 |
Why?
|
| Androstadienes | 1 | 2014 | 17 | 0.490 |
Why?
|
| Albuterol | 1 | 2014 | 21 | 0.490 |
Why?
|
| Patient Selection | 1 | 2016 | 277 | 0.480 |
Why?
|
| Mutation, Missense | 2 | 2015 | 50 | 0.480 |
Why?
|
| Patient Discharge | 1 | 2015 | 188 | 0.470 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 286 | 0.470 |
Why?
|
| Length of Stay | 1 | 2015 | 318 | 0.460 |
Why?
|
| Algorithms | 1 | 2016 | 496 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 507 | 0.420 |
Why?
|
| Health Status | 5 | 2019 | 399 | 0.410 |
Why?
|
| Time Factors | 6 | 2020 | 2152 | 0.380 |
Why?
|
| Adult | 13 | 2019 | 9367 | 0.380 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 11 | 0.370 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2010 | 6 | 0.370 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 273 | 0.370 |
Why?
|
| Respiratory Function Tests | 4 | 2019 | 108 | 0.370 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 6 | 0.360 |
Why?
|
| Delayed-Action Preparations | 3 | 2016 | 34 | 0.350 |
Why?
|
| Age Factors | 5 | 2018 | 1194 | 0.340 |
Why?
|
| Inspiratory Capacity | 2 | 2020 | 2 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 208 | 0.330 |
Why?
|
| Dyspnea | 3 | 2019 | 32 | 0.320 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 4 | 0.320 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 4000 | 0.310 |
Why?
|
| Recovery of Function | 2 | 2019 | 200 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 407 | 0.300 |
Why?
|
| Interleukin-13 | 1 | 2007 | 28 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 2 | 2007 | 262 | 0.290 |
Why?
|
| Comorbidity | 5 | 2016 | 569 | 0.290 |
Why?
|
| Environmental Exposure | 1 | 2007 | 91 | 0.290 |
Why?
|
| United States | 8 | 2020 | 3938 | 0.270 |
Why?
|
| Occupational Diseases | 1 | 2006 | 81 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 2 | 2003 | 61 | 0.260 |
Why?
|
| Risk Factors | 9 | 2019 | 3869 | 0.250 |
Why?
|
| Occupational Exposure | 2 | 2006 | 233 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 353 | 0.240 |
Why?
|
| Logistic Models | 6 | 2016 | 781 | 0.240 |
Why?
|
| Sex Factors | 5 | 2019 | 663 | 0.240 |
Why?
|
| Asbestosis | 1 | 2004 | 1 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2003 | 470 | 0.220 |
Why?
|
| Prevalence | 7 | 2019 | 981 | 0.220 |
Why?
|
| Inhalation | 2 | 2019 | 8 | 0.210 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 46 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 878 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 835 | 0.200 |
Why?
|
| Regression Analysis | 2 | 2017 | 294 | 0.200 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 184 | 0.190 |
Why?
|
| Hypercapnia | 1 | 2020 | 3 | 0.190 |
Why?
|
| Pulmonary Ventilation | 1 | 2020 | 14 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 594 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2015 | 197 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2015 | 1831 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 271 | 0.170 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2019 | 10 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 29 | 0.160 |
Why?
|
| Prognosis | 4 | 2015 | 1505 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3523 | 0.160 |
Why?
|
| Sleep | 1 | 2019 | 92 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 115 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 687 | 0.160 |
Why?
|
| North Carolina | 3 | 2019 | 1516 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 130 | 0.160 |
Why?
|
| Body Mass Index | 3 | 2016 | 923 | 0.150 |
Why?
|
| Population Surveillance | 2 | 2016 | 125 | 0.150 |
Why?
|
| Disease Management | 1 | 2018 | 126 | 0.150 |
Why?
|
| Health Education | 1 | 2018 | 157 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2018 | 147 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2010 | 897 | 0.140 |
Why?
|
| Acute Disease | 1 | 2017 | 254 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 104 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2017 | 66 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 240 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 144 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 473 | 0.130 |
Why?
|
| Stereoisomerism | 1 | 2015 | 22 | 0.130 |
Why?
|
| Genotype | 3 | 2007 | 734 | 0.120 |
Why?
|
| Melanoma | 1 | 2015 | 164 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 765 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 885 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2014 | 526 | 0.110 |
Why?
|
| Probability | 2 | 2004 | 158 | 0.110 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 12 | 0.100 |
Why?
|
| Adolescent | 4 | 2016 | 3526 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2015 | 1435 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 2283 | 0.090 |
Why?
|
| Macrophages | 2 | 2010 | 192 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2016 | 195 | 0.090 |
Why?
|
| Age Distribution | 2 | 2016 | 207 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 45 | 0.090 |
Why?
|
| Ethics, Professional | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2010 | 108 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2009 | 35 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 420 | 0.080 |
Why?
|
| ADAM Proteins | 1 | 2009 | 13 | 0.080 |
Why?
|
| Cell Survival | 1 | 2010 | 286 | 0.080 |
Why?
|
| Neoplasms | 1 | 2015 | 692 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2009 | 162 | 0.080 |
Why?
|
| Phenotype | 2 | 2009 | 639 | 0.080 |
Why?
|
| Laundering | 1 | 2007 | 4 | 0.080 |
Why?
|
| Clothing | 1 | 2007 | 6 | 0.080 |
Why?
|
| Nuclear Family | 1 | 2007 | 15 | 0.080 |
Why?
|
| Air Pollution, Indoor | 1 | 2007 | 9 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2009 | 186 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2010 | 833 | 0.070 |
Why?
|
| Homozygote | 1 | 2007 | 58 | 0.070 |
Why?
|
| Heterozygote | 1 | 2007 | 57 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1179 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 20 | 0.070 |
Why?
|
| Family Health | 1 | 2006 | 76 | 0.070 |
Why?
|
| Health Surveys | 2 | 2018 | 197 | 0.070 |
Why?
|
| South Carolina | 2 | 2016 | 31 | 0.070 |
Why?
|
| Educational Status | 1 | 2006 | 179 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 197 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2003 | 464 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 2615 | 0.060 |
Why?
|
| Allelic Imbalance | 1 | 2003 | 6 | 0.060 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 40 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 95 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 182 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 532 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 629 | 0.050 |
Why?
|
| Base Sequence | 1 | 2002 | 251 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 224 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 356 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 449 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2002 | 245 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1530 | 0.050 |
Why?
|
| Child | 1 | 2007 | 2441 | 0.050 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 1 | 0.050 |
Why?
|
| Mutation | 1 | 2002 | 488 | 0.040 |
Why?
|
| Airway Resistance | 1 | 2019 | 4 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 918 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 58 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 401 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 292 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 2280 | 0.040 |
Why?
|
| Equipment Design | 1 | 2017 | 172 | 0.040 |
Why?
|
| Haplotypes | 2 | 2009 | 220 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 19 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 99 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 125 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 125 | 0.030 |
Why?
|
| Self-Help Devices | 1 | 2013 | 8 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 231 | 0.030 |
Why?
|
| Arthritis | 1 | 2013 | 40 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 470 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 214 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2003 | 124 | 0.030 |
Why?
|
| Mental Health | 1 | 2013 | 115 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 259 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1200 | 0.030 |
Why?
|
| European Continental Ancestry Group | 2 | 2009 | 1169 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 672 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 411 | 0.020 |
Why?
|
| Constitution and Bylaws | 1 | 2009 | 3 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2009 | 20 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 220 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 584 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 957 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2003 | 8 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 20 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 32 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 75 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 137 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2002 | 7 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 39 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 72 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 99 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 140 | 0.010 |
Why?
|
| Quality of Life | 1 | 2008 | 933 | 0.010 |
Why?
|
| African Continental Ancestry Group | 1 | 2002 | 363 | 0.010 |
Why?
|